Tag: licensing
-
Princeton Lab, USDA Partner on Egg Pasteurization Process
Engineers from Princeton Plasma Physics Laboratory in Plainsboro, New Jersey and agricultural scientists from the U.S. Department of Agriculture research lab in Wyndmoor, Pennsylvania developed a process and device for pastuerizing eggs in the shell without damaging the delicate egg white. The team inventing the process filed for a patent and is seeking licensees to…
-
University, Company Partner on Computer-Based Drug Discovery
The drug discovery company Serometrix in Pittsford, New York is deploying bioinformatics software developed by University of Strathclyde in Glasgow, Scotland for identifying protein structures that show subtle clues as potential targets for drugs. Financial terms of of the licensing agreement were not disclosed. The system is a result of a collaboration between Strathclyde chemistry…
-
Diagnostics Developer, Mt. Sinai to Partner on Biomarkers
Exosome Diagnostics and Mount Sinai medical center, both in New York, are collaborating on the discovery of genetic biomarkers to build diagnostics for inflammation, cancer, and other diseases. Financial aspects of the five-year agreement were not disclosed. Exosome Diagnostics develops diagnostics based on biomarkers derived from bodily fluids, such as blood, urine, plasma, serum, and…
-
U.S. University Research Commercialization Gains in 2012
American universities and research institutes report more research discoveries headed toward the marketplace in their 2012 fiscal year, with increases in discoveries disclosed, patents, licenses and licensing income, and start-up companies formed. The Association of University Technology Managers (AUTM), the group representing campus technology transfer specialists, released today highlights of its annual survey for institutions’…
-
Bayer, Compugen to Partner on Cancer Immunotherapies
The pharmaceutical company Bayer HealthCare in Berlin and drug discovery company Compugen Ltd in Tel Aviv, Israel agreed on a development and licensing deal for two potential cancer therapies discovered by Compugen that harness the body’s immune system. The deal has a potential value to Compugen of at least $540 million. Compugen uses computational biology,…
-
FibroGen, AstraZeneca Partner on Kidney-Based Anemia Therapy
The global pharmaceutical company AstraZeneca is licensing a therapy for anemia caused by kidney disease made by FibroGen, a biotechnology company in San Francisco. The deal is valued initially at $815 million, and covers the U.S., China, and other markets not covered by an earlier FibroGen license to Astellas Pharma for commercialization in Europe, Japan,…
-
Scripps Institute, Sigma-Aldrich to Partner on Reagents
Scripps Research Institute in La Jolla, California is collaborating with Sigma-Aldrich Corp. in St. Louis to speed the availability of new chemical reagents for drug discovery to the scientific community. The deal calls for payments to Scripps from Sigma-Aldrich, a chemical and laboratory services company, although the size of the payments is not disclosed. Under…
-
University Research Leads to Non-Toxic Insect Repellant
Research by an entomology professor at University of California in Riverside led to a company licensing his discoveries that announced its first product, a non-toxic patch that repels mosquitoes for 48 hours. Olfactor Laboratories, a company co-founded by and licensing the research of Anandasankar Ray, makes the Kite mosquito patch, which yesterday started a crowd-funding…
-
Roche Advanced Skin Cancer Drug Approved in Europe
The global pharmaceutical company Roche says its drug vismodegib, marketed under the name Erivedge, received conditional approval in Europe as a treatment for adults with advanced cases of basal cell carcinoma, a form of skin cancer. Approval for the the drug, taken once a day in capsule form, is limited to cases of basal cell carcinoma that metastasize,…
-
Biotech, Cancer Center Partner on Tumor-Targeting Peptides
Blaze Bioscience, a biotechnology company in Seattle, is partnering with the Fred Hutchinson Cancer Research Center, also in Seattle, to develop and commercialize drug candidates based on engineered peptides that better target tumor cells than conventional cancer drugs. Financial amounts in the agreement were not disclosed. The Hutchinson Center is conducting research on optides —…